February 20, 2026
In 2025, the fastest-growing compliance problem in U.S. cannabinoid retail isn’t always what’s in the product—it’s whether the product’s label communicates the right things, in the right way, to the right customer, in the right jurisdiction.
A patchwork of state rules governs warnings, symbols, potency disclosures, serving statements, and “what must be on the package vs. what can be online.” At the same time, the federal government has continued to take targeted action where it already has authority—especially around deceptive marketing and child-appealing packaging—even without a single unified federal cannabinoid labeling rule.
That’s why voluntary consensus standards from ASTM International’s D37 committee matter. Even when not legally required, a harmonized labeling framework can reduce audit friction, speed multi-state launches, and lower recall risk.
This article explains the current state of the ASTM D37 cannabinoid labeling standard ecosystem, highlights the International Intoxicating Cannabinoid Product Symbol, and provides a practical adoption roadmap for brands, processors, and retailers.
Important: This is informational content, not legal advice. Always verify requirements with the relevant regulator and your counsel.
U.S. retail is increasingly multi-channel and multi-jurisdiction:
Voluntary standards help because they provide a defensible “known good” baseline. If your internal label spec is built around recognized consensus standards, you can often answer inspections, retailer questionnaires, and insurance diligence faster.
ASTM International explicitly positions D37 standards as voluntary consensus tools that governments may choose to adopt or reference. See ASTM’s overview of Committee D37 here: https://www.astm.org/membership-participation/technical-committees/committee-d37
ASTM International is a long-standing standards development organization that publishes voluntary consensus standards across many industries. Committee D37 focuses on standards relevant to cannabinoid products and operations.
ASTM D37 standards are:
They are not:
But they can be used to build a scalable “master label specification” that you then localize state-by-state.
ASTM has published a consensus standard establishing a single International Intoxicating Cannabinoid Product Symbol (IICPS).
Official ASTM press release: https://www.astm.org/news/press-releases/new-standard-provides-international-symbol-intoxicating-cannabinoids
ASTM’s standard page (purchase page, scope summary visible): https://www.astm.org/d8441_d8441m-22.html
And the symbol files have been distributed publicly by ASTM’s cannabis standards microsite resources (symbol handout PDF): https://www.astmcannabis.org/wp-content/uploads/2022/06/ASTM-Universal-Cannabis-Symbol_.pdf
Retailers and marketplaces live in the world of:
A consistent symbol across categories improves:
Even though your blog focus is “Federal,” the strongest proof of usefulness is that states have started referencing ASTM’s symbol work.
For example:
These examples matter because they show the IICPS is not just theoretical—it’s being operationalized.
Before D8441, ASTM D37 published one of its early labeling-related documents:
This guide is not “the law,” but it provides a structure for how labels can communicate key safety and identity information in a consistent way.
You can see D8233 listed in ASTM materials and FDA-hosted ASTM overview slides that summarize early D37 standards: https://www.fda.gov/media/128534/download
Most labeling failures that trigger enforcement, rework, or recalls cluster into predictable buckets.
Many states require a state-specific universal symbol. Some require the symbol not only on the package but also on individual edible units (where practicable).
A practical strategy is to:
Retail risk: shipping the wrong symbol into a state can create stop-sale orders, quarantine, relabeling costs, and distributor friction.
States disagree on:
ASTM standards don’t erase these differences, but a harmonized label architecture helps: one “potency facts” block that can be populated by jurisdiction.
Retail risk: inconsistent potency presentation increases customer complaints and increases the chance that your marketing is viewed as misleading.
Warnings often include:
Even the formatting can be regulated: font size minimums, capitalization, placement on principal display panel, and restrictions on “supplemental labeling” via QR.
For example, California’s Department of Cannabis Control publishes detailed labeling checklists and has stated that QR codes/websites are not acceptable substitutes for required supplemental labeling affixed to the product: https://www.cannabis.ca.gov/labeling/
Retail risk: if required warnings are on an insert or website instead of the package, you may fail an inspection even if the information exists somewhere.
Even without a single federal labeling rule for all cannabinoid products, federal agencies have been active where they can.
A notable example: in July 2024, the FTC and FDA sent a second set of cease-and-desist letters to companies selling delta-8 THC products in packaging designed to resemble children’s snacks.
FTC announcement: https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-fda-send-second-set-cease-desist-letters-companies-selling-products-containing-delta-8-thc
Retail risk: if your product looks like mainstream candy/snacks or uses youth-appealing trade dress, you can trigger federal attention—even if your state channel is otherwise regulated.
ASTM standards are most powerful when you implement them as an internal label control system, not as a one-off artwork tweak.
Create a single internal document that defines your baseline label components, such as:
Tie the intoxicating symbol decision to ASTM D8441/D8441M in the MLS so it’s not “marketing preference”—it’s a recognized standard.
For each target state/channel, compare your MLS to:
This is where adoption reduces friction: you’re not reinventing structure each time—you’re patching differences.
A proven tactic for multi-state operations is to split your label into modules:
If a state changes one warning sentence or symbol requirement, you only update one module.
Labeling errors are often process failures, not design failures.
Operational controls to implement:
If you already operate under a broader quality management approach, ASTM D37’s quality and recall-related standards can complement labeling controls (for example, recall/removal procedures are addressed in ASTM D8220).
If you adopt the IICPS, your training can be simpler:
Retailers can also require symbol and facts-block consistency by contract—especially marketplaces that want standardized shelf sets.
Keep a compliance binder (digital is fine) that includes:
In an inspection, being able to show a coherent labeling rationale reduces the “ad hoc” appearance that triggers deeper scrutiny.
Even if regulators don’t mandate ASTM D37 labeling standards, retailers can.
Marketplace-ready contract clauses often include:
This approach standardizes shelf sets and reduces the retailer’s risk of unknowingly selling confusingly labeled products.
At the federal level, cannabinoid labeling sits in a complicated zone. There is no single national packaging-and-labeling code for all THC-bearing consumer products sold across the country the way there is for conventional foods.
But federal risk still exists:
A voluntary standard doesn’t immunize you—but it helps establish that your label choices were made using a recognized consensus framework rather than improvisation.
Voluntary standards only reduce risk if they’re operationalized—into artwork controls, SOPs, vendor specs, and retailer contracts.
If you’re building a multi-state labeling program or want to benchmark your current labels against ASTM-aligned best practices, use https://www.cannabisregulations.ai/ to run a structured packaging and labeling gap analysis, monitor rule changes, and build an audit-ready compliance workflow.
